List of Excipients in Branded Drug RIDAURA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sebela Pharmaceuticals Inc	RIDAURA	auranofin	54766-093	BENZYL ALCOHOL
Sebela Pharmaceuticals Inc	RIDAURA	auranofin	54766-093	CELLULOSE, MICROCRYSTALLINE
Sebela Pharmaceuticals Inc	RIDAURA	auranofin	54766-093	CETYLPYRIDINIUM CHLORIDE
Sebela Pharmaceuticals Inc	RIDAURA	auranofin	54766-093	D&C RED NO. 33
Sebela Pharmaceuticals Inc	RIDAURA	auranofin	54766-093	FD&C BLUE NO. 1
Sebela Pharmaceuticals Inc	RIDAURA	auranofin	54766-093	FD&C RED NO. 40

Ridaura (Auranofin) Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Ridaura is a 3 mg oral capsule containing auranofin, an organogold compound approved for rheumatoid arthritis. Its original formulation has limited differentiation beyond conventional capsule excipients. The main commercial opportunities are a lower-cost generic, a lactose-free or allergy-conscious reformulation, improved dose flexibility, and repurposing through a 505(b)(2) pathway. The original Ridaura patent and regulatory exclusivity periods expired decades ago, leaving formulation execution, clinical positioning, manufacturing controls, and regulatory strategy as the primary barriers.

What is Ridaura and how is it formulated?

Ridaura contains 3 mg of auranofin in a hard gelatin capsule. Auranofin is practically insoluble in water and is administered orally for the treatment of active rheumatoid arthritis in adults who have responded inadequately to, or cannot tolerate, other antirheumatic therapy [1].

The labeled inactive ingredients include:

Formulation component	Role
Lactose	Diluent and capsule-fill bulking agent
Povidone	Binder and granulation aid
Sodium starch glycolate	Disintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Gelatin	Capsule shell
Titanium dioxide	Opacifier and colorant
Yellow iron oxide	Capsule colorant

The exact excipient composition is commercially important because auranofin is a low-dose, high-potency drug substance. At a 3 mg fill strength, uniformity of dosage units, powder segregation, blend homogeneity, and assay sensitivity are more important than bulk-filling efficiency.

The original Ridaura formulation uses a conventional immediate-release capsule platform. It does not establish a high technical barrier to a generic manufacturer with adequate control of low-dose blending and content uniformity.

What excipient strategy is most suitable for a Ridaura generic?

The lowest-risk strategy is a capsule formulation that closely matches the reference product’s qualitative excipient profile while optimizing processing and supply economics.

Option 1: Reference-like lactose formulation

A reference-like formulation would retain lactose, povidone, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. This approach can simplify formulation development and reduce the risk of unexpected dissolution differences.

Key development priorities include:

• geometric dilution of auranofin into the primary diluent;
• low-shear blending to limit segregation;
• validated blend and capsule-fill sampling;
• control of lubricant mixing time;
• finished-product assay and content-uniformity testing;
• comparative dissolution across multiple pH conditions;
• protection from excessive moisture and light during storage.

This option is likely to have the shortest development timeline and the lowest clinical or regulatory risk for an ANDA.

Option 2: Lactose-free capsule

A lactose-free formulation could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, pregelatinized starch, or a combination of these excipients. The commercial rationale would be patient differentiation rather than a fundamental improvement in auranofin delivery.

Potential benefits include:

• access for patients with lactose intolerance or excipient sensitivity;
• broader suitability for specialty-pharmacy distribution;
• simplified positioning against a lactose-containing reference product;
• potential use of hard hypromellose capsules instead of gelatin.

The principal technical risk is that alternative diluents may change powder density, electrostatic behavior, flow, and blend uniformity. Auranofin’s low dose means that a replacement excipient cannot be selected solely on the basis of compendial precedent.

Option 3: Direct-compression or co-processed excipient platform

A co-processed microcrystalline cellulose and mannitol system could improve flow and reduce the need for multiple functional excipients. This approach may lower manufacturing complexity but requires more extensive process development.

A direct-compression platform is more attractive for a tablet than for a capsule. A tablet could provide lower packaging cost, easier automated inspection, and potentially more stable supply-chain economics. It would also create greater risk because tablet hardness, disintegration, dissolution, and auranofin distribution would need to be demonstrated against the capsule reference.

Option 4: Modified-release or gastroprotective formulation

A delayed-release, enteric-coated, or modified-release product could seek a differentiated clinical profile, but the regulatory and development burden would be materially higher. Auranofin is associated with gastrointestinal adverse reactions, including diarrhea and abdominal pain [1]. A formulation intended to reduce upper-gastrointestinal exposure could have commercial value, but it would require evidence that the altered delivery profile improves safety or tolerability without compromising efficacy.

This is a reformulation or 505(b)(2) opportunity, not a low-risk ANDA strategy.

What excipient risks affect auranofin manufacturing?

Auranofin contains gold and is chemically distinct from conventional small-molecule APIs. The formulation program should treat compatibility and impurity control as core development questions.

Moisture and solid-state control

The selected excipient system should be evaluated for:

• water activity;
• hygroscopicity;
• changes in capsule-shell moisture;
• API degradation under accelerated conditions;
• interaction with reducing or oxidizing impurities;
• extractables and leachables from packaging;
• light exposure during processing and storage.

The original product’s use of a capsule shell and conventional powder excipients does not eliminate the need for product-specific compatibility work. Auranofin’s low dose increases the impact of localized incompatibility because small absolute losses can produce large percentage changes in assay.

Lubricant level

Magnesium stearate can reduce wettability and slow dissolution when overmixed or used at excessive concentrations. A generic manufacturer should establish a narrow operating range for lubricant concentration and mixing time. Alternative lubricants may be technically possible, but any change should be justified with dissolution, impurity, and stability data.

Capsule-shell selection

A hard gelatin shell most closely reflects the historical product. Hypromellose capsules could support a lactose-free or animal-origin-free commercial position. The tradeoff is additional evaluation of moisture transfer, shell brittleness, disintegration, and supply reliability.

Colorants and patient positioning

Yellow iron oxide and titanium dioxide are not central to drug performance but affect visual similarity, patient acceptance, and manufacturing cost. A colorant-free or simplified shell could support a clean-label strategy, subject to applicable FDA requirements and product-identification controls.

What patents protect Ridaura and auranofin?

The original composition-of-matter and product patents associated with auranofin are long expired. Ridaura was approved in the United States in 1985, and the product’s original regulatory exclusivity and patent terms cannot block a current generic program [2].

The practical patent position is:

Rights category	Current commercial relevance
Original auranofin composition patents	Expired
Original Ridaura formulation patents	Expired or no longer commercially blocking
Original rheumatoid arthritis method patents	Expired
Orange Book-listed Ridaura patents	No meaningful blocking estate identified in current product strategy
New formulation patents	Potentially available for novel delivery or excipient systems
New method-of-use patents	Potentially available for new diseases or patient populations
Manufacturing-process patents	Potentially available if the process is genuinely novel and non-obvious

A company cannot obtain strong patent protection merely by substituting one routine diluent for another. A defensible formulation patent would need to claim a non-obvious combination, such as a specific stability-enhancing system, a defined dissolution profile linked to clinical performance, a novel delivery mechanism, or a manufacturing process that solves a demonstrated problem.

What is the Orange Book status of Ridaura?

Ridaura is associated with FDA NDA 018780 and the active ingredient auranofin [2]. The product’s commercial status should be distinguished from its historical approval status.

The relevant points for an entrant are:

1. FDA approval of the reference product establishes the regulatory basis for an ANDA.
2. Expired patent rights do not create a current exclusivity barrier.
3. A generic applicant would need to address any applicable listed patents in the Orange Book at the time of filing.
4. If no unexpired listed patent remains, patent certification risk is substantially reduced.
5. The applicant would still need to address bioequivalence, product quality, labeling, and manufacturing requirements.

Because Ridaura is an older, low-volume product, the principal regulatory risk is likely product development and commercial supply rather than patent litigation.

When does Ridaura lose exclusivity?

Ridaura lost meaningful market exclusivity many years ago. The product was approved in 1985, so the five-year new chemical entity exclusivity period and the original patent terms expired long before the current generic opportunity [2, 3].

Exclusivity category	Ridaura position
New chemical entity exclusivity	Expired
Original product patent term	Expired
Pediatric exclusivity	No current blocking period
Orphan exclusivity	Not applicable to the approved rheumatoid arthritis indication
Data exclusivity for a current entrant	Not a practical barrier for an old product
Current biologic exclusivity	Not applicable

A new sponsor could seek separate exclusivity for a new indication or a qualifying reformulation, but that would require a new regulatory pathway and supporting clinical or pharmacological evidence.

Are there Paragraph IV challenges or patent litigation affecting Ridaura?

No active patent dispute is central to the current Ridaura commercial analysis. The absence of a meaningful unexpired Orange Book patent estate reduces the value of a Paragraph IV strategy.

A generic applicant could still face:

• a patent-listing dispute if a new patent were listed;
• product-specific patent claims from a later reformulation sponsor;
• trademark or trade-dress issues involving the Ridaura name or capsule appearance;
• manufacturing or supply disputes unrelated to Orange Book patents.

The likely entry model is therefore a conventional ANDA rather than a litigation-led Paragraph IV launch.

Is there biosimilar risk for Ridaura?

No. Auranofin is a chemically synthesized small molecule, not a biologic. Ridaura is not subject to the biosimilar pathway under the Public Health Service Act. Competition would arise through generic auranofin products or through 505(b)(2) reformulations, not biosimilars [4].

What generic entry risks exist for auranofin?

The main risks are technical and commercial.

Technical risks

• low-dose blend uniformity;
• incomplete understanding of API-excipient compatibility;
• dissolution differences caused by lubricant level;
• stability changes from capsule-shell moisture;
• limited access to a qualified auranofin API supplier;
• analytical-method transfer and impurity characterization;
• limited clinical literature supporting alternative dosage forms.

Regulatory risks

An ANDA sponsor must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. A change from capsule to tablet, immediate release to modified release, or conventional excipients to a novel delivery system may move the program toward a 505(b)(2) application rather than a standard ANDA [5].

Commercial risks

Ridaura historically served a narrow rheumatoid arthritis population. Modern treatment has shifted toward methotrexate, biologic disease-modifying antirheumatic drugs, targeted synthetic DMARDs, and other therapies. A generic entrant may obtain approval without achieving meaningful sales if prescribers have limited interest in oral gold therapy.

The market may still support a niche product where:

• competitors have discontinued supply;
• rheumatologists seek an oral alternative for selected patients;
• specialty pharmacies can manage limited-volume distribution;
• a manufacturer can maintain reliable supply with minimal commercial overhead;
• the product is priced below competing branded therapies.

What commercial opportunities exist for Ridaura excipients and reformulations?

Low-cost generic capsule

This is the clearest opportunity. The product can use established excipients and focus on manufacturing reliability, API sourcing, and controlled distribution. The opportunity is most attractive to a company with an existing solid-dose facility and low incremental development cost.

Lactose-free or animal-origin-free capsule

This strategy offers modest differentiation. It may improve formulary or pharmacy acceptance but is unlikely to justify a large price premium without evidence of superior tolerability or adherence.

Lower-dose or dose-flexible presentation

The 3 mg capsule limits dose adjustment. A 1 mg or scored tablet could provide more flexible titration, but such a product would require careful clinical and regulatory positioning. A lower-dose product could be useful for patients who experience dose-related toxicity, although the commercial population would need to be established.

Combination or co-packaged therapy

Auranofin could theoretically be co-packaged with an established rheumatoid arthritis therapy, but combination claims and clinical positioning would create significant regulatory complexity. A co-packaged product is more feasible than a fixed-dose combination if the commercial rationale is adherence or treatment sequencing.

Repurposing beyond rheumatoid arthritis

Auranofin has been investigated in areas including infectious disease, oncology, parasitic disease, and neurodegenerative disease. These programs are separate from Ridaura’s approved indication and would require new clinical evidence. If a new indication produces meaningful efficacy data, formulation patents and method-of-use patents could support a 505(b)(2) or full new-drug strategy [6].

How strong is the patent estate for a new Ridaura formulation?

The legacy estate is weak as a commercial barrier because the original rights have expired. A new estate could be moderate to strong only if it includes claims that competitors cannot easily design around.

Patentable opportunities may include:

• a defined excipient ratio that improves auranofin stability;
• a moisture-controlled capsule system;
• a solid dispersion or nanoparticle formulation;
• a gastroprotective delivery system;
• a specific dissolution profile tied to pharmacokinetic performance;
• a new indication supported by clinical evidence;
• a manufacturing process that improves content uniformity or reduces impurities.

Routine substitution of lactose with microcrystalline cellulose, changing capsule color, or using a standard disintegrant would generally provide weak patent protection. The stronger commercial strategy is to combine a technically meaningful formulation improvement with regulatory exclusivity and a focused market position.

How does Ridaura compare with competing rheumatoid arthritis therapies?

Product class	Ridaura position
Methotrexate	Generally stronger first-line position and broader clinical use
Hydroxychloroquine	Established oral alternative with different risk profile
Sulfasalazine	Established conventional DMARD with broader current use
Biologic DMARDs	Higher cost, injectable or infused, and clinically dominant in refractory disease
Targeted synthetic DMARDs	Modern oral alternatives with stronger commercial infrastructure
Generic auranofin	Low-cost niche opportunity with limited market expansion potential

Ridaura’s commercial advantage is oral administration and potential low price. Its disadvantages are older clinical positioning, adverse-effect concerns, monitoring requirements, and competition from better-established DMARDs.

What revenue exposure should investors expect?

Publicly reliable current revenue estimates for Ridaura are limited. The product is an older, niche medicine rather than a major branded asset. Revenue exposure for a generic entrant would likely depend on supply continuity, the number of approved competitors, pharmacy substitution, and API cost.

A financial model should prioritize:

• annual prescription volume;
• number of active suppliers;
• average selling price after generic entry;
• gross margin after API and quality-control costs;
• expected shortage or discontinuation risk;
• specialty-pharmacy and wholesaler deductions;
• pharmacovigilance and regulatory-maintenance costs.

The commercial case is more consistent with a focused niche product than with a high-growth specialty pharmaceutical.

Key Takeaways

• Ridaura contains 3 mg of auranofin in a conventional immediate-release hard gelatin capsule.
• The labeled excipients include lactose, povidone, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, gelatin, titanium dioxide, and yellow iron oxide.
• The original patent and regulatory exclusivity barriers have expired.
• A reference-like capsule is the lowest-risk generic strategy.
• A lactose-free or hypromellose-capsule formulation provides modest differentiation but limited standalone patent strength.
• Modified-release, gastroprotective, and new-indication products could support 505(b)(2) opportunities.
• Ridaura has no biosimilar pathway because auranofin is a synthetic small molecule.
• The main barriers are low-dose content uniformity, API supply, stability, dissolution, and limited market demand.
• Commercial potential is likely niche and supply-driven rather than comparable to modern rheumatoid arthritis therapies.

FAQs

Can a generic manufacturer replace lactose in Ridaura?

Yes. A generic manufacturer can develop a lactose-free formulation, but the replacement must support equivalent performance, content uniformity, dissolution, stability, and regulatory requirements.

Is auranofin still protected by composition-of-matter patents?

The original auranofin composition-of-matter patent rights are expired. Any current protection would need to arise from a later formulation, manufacturing process, or method-of-use patent.

Would a Ridaura tablet require an ANDA?

Not necessarily. A tablet that differs materially from the capsule reference may require a 505(b)(2) application, depending on the extent of the dosage-form and formulation differences.

Can auranofin receive orphan-drug exclusivity for a new indication?

Potentially, if a sponsor develops a qualifying rare-disease indication and meets FDA orphan-drug requirements. That would be separate from Ridaura’s approved rheumatoid arthritis indication.

What is the most attractive excipient opportunity for auranofin?

A lactose-free, moisture-controlled capsule is the most practical near-term opportunity. A modified-release or gastroprotective system has greater differentiation potential but also carries substantially higher clinical and regulatory risk.

References

1. U.S. National Library of Medicine. (n.d.). Ridaura- auranofin capsule. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Ridaura, NDA 018780.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry.
5. U.S. Food and Drug Administration. (2020). Applications covered by section 505(b)(2): Guidance for industry.
6. National Library of Medicine. (n.d.). Auranofin clinical studies. ClinicalTrials.gov.